[The treatment of pre-malignant hyperplasias of the endometrium with progesterone-carrying intra-uterine devices (author's transl)].
The local administration of progestional agents for the treatment of adenomatous hyperplasia of the endometrium is insufficient for two reasons: 1. The locally applied progestational agent does not reach the total surface of the endometrium especially not in the uterine fundus or in the tubal cornua. This is frequently due to uterine myomata and to the T-shape of the intra-uterine device which does not contain progestational agents within the T. 2. The progestational agent released by the intra-uterine device does not reach the deeper layers of the endometrium. It is therefore possible that the deeper layers of the endometrium undergo malignant change. At present it is therefore necessary to administer progestational agents in the treatment of adenotamous hyperplasias of the endometrium systemically.
D004714:Endometrial Hyperplasia / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007436:Intrauterine Devices, Medicated; D011230:Precancerous Conditions / Q000188:drug therapy*; D011374:Progesterone / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D011374:Progesterone
Zur klinischen Anwendbarkeit gestagenbeladener Intrauterinpessare bei der Behandlung präkanzeröser Hyperplasien.